Cloning and expression of a bovine adenosine A1 receptor cDNA  by Tucker, Amy L. et al.
February 1992 Volume 297, number 1,2, 107-I I1 FEBS lOG79 
Q 1492 Federation of European Biochemical Societies 00I45793/92/%5.00 
Cloning and expression of a bovine adenosine Al receptor cDNA 
Amy L. TuckePb, Joel Linden”, Anna S. Robevab, Drew D. D’Angelo’ and Kevin R. Lynch”” 
Deparrrnetm of “Biocltetni.wy, “lttternui Medicitfe (Cardiology) atId PPiwtuucoiogy, Umversiry of Virgilrh, Charlotfesville, Virgbiu 
22908, USA 
Received 2 Decenker 1991 
A bovine brain adcnosinc A, receptor cDNA encoding 3 326 amino acid protein has been identified. This cDNA. which encodes a protein 290% 
identical to analogous rat and dog receptors, was uansiently expressed inCOS-1 cells. Recombinanl receptors exhibited the features of bovine A, 
receptors that distinguish it from rat and canine reccplors, including subnanomolar A’, for I ,3-dipropyl-&cyclopentylxanthine, R-phenylisopropyl- 
adenosine (R-PIA) and xanthine amino conjugale, and lhe distinct potency order: R-PIA > S-PIA >> Y-N-elhylcarboxamidoadenosine 
5 2’.chloroadcnosine. The results indicate that Ihe pharmacological diffcrcnces between A, adenosinc receptors among species result from only 
minor differences in reccplor structures. 
Purincrgic; G protein-coupled receptor; RDC? 
1. INTRODUCTION 
Adenosine modulates a number of physiologic func- 
tions and has important effects on the cardiovascular [l] 
and nervous systems [2]. The actions of adenosine 
appear to be mediated through specific G protein- 
coupled cell surface receptors [3]. Based on biochemical 
studies of adenylate cyclase activity and pharmacologic 
studies involving relative affinities for adenosine 
analogs, two major subtypes of adenosine receptors 
have been identified. The adenosine AI-type receptors 
typically inhibit adenylate cyclase and show higher af- 
finity for P-substituted adenosine analogs than for Y- 
substituted analogs, Conversely, adenosine A?- type re- 
ceptors stimulate adenylate cyclase and show the 
reverse potency order [1,3,4]. That there are two sub- 
types of AZ receptors (Ab and A?,,) seems clear from 
pharmacological data [S]. The Aza subtype has a dis- 
tribution limited to the striatum, nucleus accumbens 
and olfactory tubercle and has been cloned [6]. Whether 
or not there are subtypes of A, receptors is uncertain. 
Binding to A, receptors varies qualitatively from tissue 
to tissue [7], and also varies markedly among species [3]. 
ADbreviurions: G proteins. guaninc nucleolide binding proteins; PIA, 
N-6-phenylisopropyladenosinc; NECA,, S’-N-ethylcarboxamidoadc- 
nosine; AIIA. M-aminobcnzylodenosinc; CPA, Na-cyclopentylade- 
nosine; CHA, Ivb-cyclohcayladenosine; CADO, 2thloroadenosine; 
BW-A844, 3-aminophenethyl-1-propyl-B-eyclopentylxanIhine; BW- 
Al433, 1.3,dipropyl-8-phcnyl(p-acrylate)xanthine; CPT, cyclopen- 
tylthcophylline; I&, concentration required to inhibit binding by 
50%. 
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A, adenosine receptor cloning has been reported for 
two species, the dog and the rat [8-l 11. Binding data 
from recombinant rat receptors expressed in COS cells 
correlated well with published data on binding to rat 
brain receptors [10-141. Dog recombinant receptors ex- 
pressed in COS cells bind ligands differently from rat 
receptors (little discrimination between A-PIA and 
NECA [9]) but similar to native receptors found on 
canine brain membranes. The bovine receptor pharma- 
cology, which is very distinct from rat, canine and 
human [12] receptors, is maintained when purified 
bovine receptors are reconstituted into human platelet 
membranes [IS]. These data suggest that structural dif- 
ferences in A, adenosine receptors among species are 
responsible for the differences een in structure-activity 
profiles. We describe the cloning of an A, adenosine 
receptor from bovine brain. A detailed comparison of 
the pharmacology of recombinant receptors with that 
seen in native brain membranes reveals a strong simi- 
larity between ative and recombinant receptors, indi- 
cating that although there is considerable similarity in 
receptor structure among species, the unusual bovine 
pharmacology can be attributed to the structure of the 
bovine receptor and not to the composition of 
membrane lipids or G proteins. 
2. MATERIALS AND METHODS 
Drugs were obtained from the Sibma Chemical Co. with the follow- 
ina excentions: BW-A844. BW-Al433 and DPCPX were gifts of Dr. 
S&n Daluge of the Burrdughs Wellcome Co. NECA, CPA: XACand 
CPT were from Research Biochemicals Inc. CHA was from Cal- 
bioehcm. 
2.1. cDNA librury scrr~wing cold DNA sequencing 
Two oligonuclco~ides (YTGTCCTCATCCfCACCCAGAG- 
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CTCCAT and fGGTAGCGGTCCACGGCAATCGCCAG- 
CAGGGCCAGGATGGAGCTC) were designed. These encode a 
portion of the putative third tmnsmembrane tcgion of the dog adc- 
nosinc A, recepior (RDC7) scqucnce [9]. The 3’ terminal nonamers of 
the oligonucleotides arc complementary; a radiolabeled probe was 
made by the action of the Klenow fragment of DNA polymerase I on 
the annealed oligonuclcotide t mplates in the presence of [“‘P]dCTP 
and three unlabeled eoxynucleosidc triphosphates. The resulting 
residue DNA fragment, which had an average speciftc activity of4 x 
IO6 dpm./pmol, was denatured and used to screen duplicate nitrocel- 
lulose filters lifted from a bovine brain cDNA library (a gift from 
R.A.F. Dixon) in the vector ?-ZAP. One million recombinnnts were 
screened. Fillers were hybridized at 42OC in 5x SSPE [16], 5x 
Denhardt’s olution [la], 0.2% sodium dodecyl sulfate, 0.05% sodium 
pyrophosphate, and 0.1 mg/ml sheared herring sperm for 36 hours. 
Filters were washed in a final wash buffer of 0.2% SSPE and 0.05% 
sodium pyrophosphaic for I h at 42°C. Phage generating positive 
signals were plaque purified, followed by in viva excision of the nested 
Blucscript plasmids using helper phage according to the Stratagene 
protocol, DNA sequence was determined along both strands using the 
Sanger dideoxynucleotide chain termination method [17]. Oligonu- 
cleotide primers used were either vector-specific or designed from 
conserved regions of known sequences from the canine and rat ade- 
nosine A, receptors. Sequencing primers were synthcsixti by Dr. John 
Zysk of the American Cyanamid Co. Sequence analysis was done 
using the GCG software. 
The bovine adenosine A, receptor cDNA was subcloned into the 
expression plasmid CLDN 1 OB (a gift from Dr. M. Rcff, SK&F Labo- 
ratories). This plasmid. which contains the immediate arly CMV 
promoter and an SV40 ori was used to transfect COS-I cells using the 
DEAE-dextmn method of Cullen [IS]. 5 lug of CsCI-purified plasmid 
DNA were used for each 60 mm tissue culture plate containing ap 
proximately 2x IO6 cells, 72 h after transfeclion cell monolayers were 
scraped into 2.5 mi of Buffer A (I mM EDT.%, 0.1 mM bcnzamidine, 
IO mM HEPES, pH 7,4) per plate. In parallel with frozen bovine brain 
(Pel-Freeze). the cells were homogenized using a Brinkmann polytron, 
setting 5. for IO s. The homogenates were centrifuged at 20,000 x g 
for 30 min and resuspended in HE buffer (10 mM HEPES, IO mM 
EDTA, 0.1 mM benramidine and 0.1 mM phenylmethylsnlfonyl- 
fluoride). The membranes were washed twice by centrifugation, The 
resulting pellets were resuspended in HE at a final protein concentra- 
tion of 1 mdml. Membranes were aliquotted and frozen until USC, at 
which time they were diluted to concentrations reported for each 
assay. Proteins were determined from fluorescamine fluorescence 
using bovine serum albumin standards, 
Binding assays were performed using an antagonisi, [1z51]13W-A844 
[l9], and an agonist, [“‘I]ABA [ZO]. For binding assays membrtncs 
were thawed and 5 U/ml of admosinc deaminase (Sigma) was added. 
Membranes (50 yl) were added to 50 ~1 of HE buffer containing 4.9 
mM MgC&, 0.01% CHAPS, and rndioligand with or without the 
indicnted concentrations of unlabeled competitors. Non-specific bind- 
ing was measured in the presence of IOpM R-PIA. Binding reactions 
were incubated at 25OC for 120 min and terminated by rapid Bltration 
through Whntman glnss fiber (GF/C) filters using a Drandel Cell 
Harvester. Filters were washed 3-times with 3 ml of ice-cold buffer 
consisting of 10 mM Tris-Cl, 1 mM MgCI:, pH 7.4. 
2.3. Data unalysis 
Saturation data were analyzed using a single-site binding model. 
I& values were derived from competition curves and 4 values calcu- 
lnted as described previously [2l]. 
3. RESULTS AND DISCUSSION 
An oligonucleotide probe encoding the putative third 
transmembrane r gion of the canine Al adenosine re- 
ceptor was used to screen IO6 recombinants from a 
bovine brain cDNA library. Ten positive signals were 
plaque-purified, and a portion of the DNA sequences 
was determined. This analysis howed that eight of the 
clones were derived from the same rnRNA population; 
some of these cDNAs were replicates (i.e. sibs). One 2.8 
kbp cDNA clone (pBOV13, Gcnbank accession no. 
X63592), which contained a complete xtended transla- 
tional reading frame encoding a protein of 326 amino 
acids, was chosen for further analysis. Fig. 1 shows the 
conceptualized amino acid sequence of pBOV13 com- 
pared with the analogous dog and rat sequences [9-l 11. 
As is the case with numerous members of the seven 
transmembrane helix superfamily, the amino acid se- 
quences of the different species are very similar (>90% 
identity). These receptors hare features common to 
other G protein-linked receptors including 1 or 2 gly- 
cosylation consensus ites (although these occur in the 
2nd exofacial loop rather than near the amino terminus) 
and several amino acids that are highly conserved in the 
seven transmembrane helix superfamily [22]. Notably 
absent from all three species are clusters of serines and 
threonines near the carboxyl terminus that are present 
in several G protein-linked receptors and are thought o 
be phosphorylated uring receptor down-regulation. 
Interestingly, the divergence among the three sequences 
occurs in three small clusters: amino acids 151-156 (sec- 
ond exofacial loop), 261-270 (third exofacial loop), and 
at the carboxyl terminus. 
To determine the binding characteristics of bovine 
1 50 
C"*' ?lPPSISAPQA AYlGIEVLlA LVSVPCHVLV IWAVKVNQAL RDA'I'FC171VS 
rat . ..Y...... . . . . . . . . . . . . . . . . . . . . . ..I...... . . . . ..a... 
dos . ..A...... ..a,....,, . . . . . . ..a. .a........ . . ..a..... 
51 100 
c 0,~ LAVADVAVCA LVlPL,AlLlN IGPKTYFIITC LKVACPVLIL TQSS1LALI.A 
rat . . . . ...*.* . . . . . . . . . . ,.. . . ..a. .a........ s......... Q 
dog ,..,,.,,,, ..,.,,,.,* ,.....I... .Y........ I.I.I....I 
101 150 
co\< ?l,AVDRYLKVK IPLRYKTVVT PRRAVVAITG Ck‘ILSFVVGL TP!IFCWXSLS 
I-OL I......... . . . . ...*.. Q...A...A. . . . ..L..n. ..I....... 
dog l......... . . . . . . . . . . . . ..A....~. . . . . . . ..a. ..L....R.G 
151 xx 
COW AVERDWLANC SVGEPVlECQ FEKVlSElEYM VYFNFNU‘VL PPLLWVLIY 
rat V..Q..K... . . . . . ..K.I. .*...,.... . ...*..... ..a......* 
dog BAQ.A.A... .C.....K.T: . . . ..a.... . . ..a..... . . . . . . . ..I 
"01 250 
COW >IEVI:YLlREQ LSSKVSASSG DPQKYYCKGL KIAKSLALIL FLFALSWLPL 
rrl~ L......... .N........ . . . . . . ..a. . . ..a..... ..I....... 
dog L.......H. ,G........ . ..n...... a......... ,.,.....** 
751 300 
cow HILSCITLIX I'SCHMI'RILI YIAIFLSHGK SA!lNPIVYhF RIQKFRVTFL 
rat ,,,....... .T.Q...... . . . ..a.... n......... . ..I-!...... 
dog . . . . . . . . . . ,..RK.S..FI . . . . ..T... ,,....,... ..,......I 
rat . . . . . . . . . . .K......L. E.KAE. 
do6 ,,...,,.,. .T..V...P. E.A.H. 
Fig. I. Comparison oTpBOVI3 amino acid sequence to that of rat and 
dog adenosine A, receptors. The bovine sequence is shown on top with 
rat nnd dog below. Dots (,) indicate amino acid identity. Letters are 
used to indicate changes betweem the rat or dog from and the bovine 
sequence. 
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Fig. 2. Saturation isotherm and Scotchard plot (inset) of [“‘I]BW- 
A844 binding to membranes prepared from transfectcd COS-I cells 
(G, 0.008 mg protein/tube) und to membranes prepared from nutivr 
bovine brain (0.0.39 mgprotcin/tubc). Only specitic binding isshown. 
Non-speciftc binding was mcasurcd in the presence of IO PM R-PIA 
and reprcscntcd less than 15% of total binding at the radioliyund Kn. 
Each point is the mean of triplicate determinations. Bound units for 
~hc Scatchard plots are cxprcsscd as fmol per assay tube 
adenosine receptors, the cDNA was expressed in COS 
cells and binding compared with native brain receptors 
assayed in parallel. Untransfected cells ‘did not show 
specific adcnosine analog binding (data not shcwn). 
Fig. 2 shows high affinity, specific, and saturable bind- 
ing of [“s1]BWA844 [19]. The maximum binding ca- 
pacity (B,,,,) of the transfected COS-1 cell membranes 
was 2.31 pmol/mg protein compared to 0.35 pmol/mg 
protein for bovine brain membranes. K,, values were 
0.24 nM and 0.13 nM for transfected and native 
membrane systems, respectively. To estimate the rela- 
tive fraction of coupling of the adenosine A, receptors 
to G proteins in the two systems, saturation binding was 
also performed using [lz51]ABA [20] over a concentra- 
tion range chosen to selectively label only high aftinity 
coupled receptors (Fig. 3). The B,,,,, values for recom- 
binant and native membranes was 0.91 pmol/mg protein 
and 0.18 pmol/mg protein, respectively; KD values were 
0.94 nM and 0.60 nM. Comparison of the antagonist to 
the agonist B,,,, suggested a coupling fraction of 39% 
0.0 0.5 1 .o 1.5 2.0 2.5 
Free 1251-ABA (nM) 
Fig. 3. Saturation isotherm and Scatchard plot (inset) of [rJSI]ABA 
binding. The protocol is analogous to that described in Fig. 2. Non- 
specific binding is less than 5% of total binding at the radioligand KD. 
Table I 
Competition by various drugs for binding of[?]ABA to recombinant 
receptors expressed in COS cells and to receptors in native bovine 
brain membranes* 
Ki (nM) 
Atlrf.tgolfisrr 
XAC 
DPCPX 
BW-A 1433 
5.CPT 
BW-A844 
Thcophyllinc 
Recu,,rhinm1r NUfilV 
0.93 0.25 
I .74 0.5 
3.02 1.35 
4.57 3.39 
646 2. I4 
26.000 6.460 
Agfr/li.srs 
R-PIA 0.26 0.50 
CHA 0.69 2.04 
CPA I.17 1.86 
SPIA I .58 3.39 
NECA 646 14.5 
CAD0 56.2 89.1 
*lCp, determinations were derived from competition curvcsconsisting 
of eight concentrations of competing drugs assayed in triplicate and 
were fit to the equation: 8=B,,_(~~,~NS).D”/(IC,” + D”). whcrc 
B = bound rudioligand. NS = non specifkally bound ndioligand. D 
= the concentration of drug, and n = slope factor. Ki values wcrc 
determined rrom IC, values with correction for bindingofradioligand 
and competing drugs to receptors. For each competing drug, rccom- 
binant und native receptors wcrc assayed in the same cxperimcnt. Each 
assay tube (0. I ml) contuined 17.4 fmol of [rsl]ABA and 5 puy of COS 
membranes or 24.5 ,ug of bovine brain membranes. 
in the transfected COS cell membranes vs. 50% in the 
brain membranes. In additional experiments (not 
shown) competition by the agonist R-PIA for [‘“51]13W- 
AS44 binding was biphasic and monophasic in the 
absence and presence of 30 ,uM GTPTS, respectively, 
which is also indicative of partial coupling of both na- 
tive and recombinant receptors to G proteins. 
To characterize further the pBOVl3 encoded re- 
ceptor, binding competition curves were performed 
using six adenosine A, agonist (Fig. 4) and six antag- 
onist (Fig. 5) ligands. The rank order of potency of the 
drugs used was similar for native and recombinant re- 
ceptors. For agonists, the nffmity order of A-PIA 2 
S-PIA > NECA agrees with published data for A, 
adenosine receptors purified from bovine brain using an 
XAC affinity column [23]. In contrast, the ‘classic’ [14] 
A, subtype binding order, as seen in brain receptors 
from rat and several other species, is R-PIA 1 NECA 
> SPIA [l&13]. Of the antagonists tested, XAC ex- 
hibited the highest affinity, followed by DPCPX > 
BWA1433 = CPT > BWAS44 B> theophylline (Ki val- 
ues are listed in Table I). Characteristic of bovine re- 
ceptors is the very high afinity (c I nivi i&j of several 
of these ligands (R-PIA, XAC, [“51]BW AS44, 
[“‘I]ABA and DPCPX). 
The sequence of the pBOV 13 clone suggests trongly 
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1.2 1.2 
RECOMBINANT -1 RECOMBlNANt 
1.2 
NATIVE 
0.4 
0.2,. 
0.01 : : : ; : : : ; : ; I 
-13-12 -11 -10 -9 -8 -7 -8 -5 -4 -3 -2 
[Agonist] (log M) 
Fig. 4. Competition by agonists for binding to DOVl3~transfected 
COS- I cell membranes and bovine brain membranes. [‘“51]AUA (17.4 
fmol) and tight concentrations of unlabeled competing drug were 
iIsSdyed in triplicate. Binding conditions, equations used for curve 
fitting and derived K, values arc found in Table 1. 
that it represents the bovine homolog of the cloned rat 
and dog brain adenosine A, receptors. The pBOV13 
protein binding profile, as determined with both ago- 
nists and antagonists, reflects that seen with the native 
receptor in bovine brain membranes. It has long been 
known that there are species-specific binding profiles 
for adenosine A, receptors. The differences seen in the 
native membranes are mimicked in the recombinant 
receptors, uggesting structural differences in the recep- 
tors are responsible. 
A, receptors couple to several known effector systems 
and seem to be able to associate with different G pro- 
teins in vivo [24]. The affinities of ligands for A, recep- 
tors can vary not only from species to species, but also 
within a given species from tissue to tissue. For exam- 
ple, NECA affinity is approximately oo-fold less in rat 
adipose tissue than in heart or brain [3], raising the 
possibility of subtypes. Whether binding differences are 
secondary to structural differences in receptors or to 
environmental factors such as coupling can be ad- 
dressed in part by molecular cloning and subsequent 
expression of the receptors. The cloning of the rat and 
dog, and now cow, A, receptors allows comparison of 
binding to recombinant receptors expressed in similar 
tissue nvironments. From Fig. 1 it can be seen that the 
amino acid sequences of the rat, dog and cow receptors 
are highly conserved over most of their length, with the 
exception of the second and third exofacial loops and 
the carboxy terminus. Perhaps these regions are respon- 
0 
-O-ME0 
-.-cm 
0 DPCPX 
L% 
1.2 
NATIVE 
0.0-l : i : : : ; : : : I 
-13 -12 -11 -10 -9 -8 -7 -6 -3 -4 -3 -2 
[Antagonist] (log M) 
Fig. 5, Competition by antagonists for binding to BOVI 3-transfected 
COS-I cell membranes. Conditions are analogous to Fig. 4. 
sible for unique binding profiles between species; alter- 
natively, these regions may be hypervariable because 
they are not important in ligand recognition, and spe- 
cies differences may be due to the minor differences in 
amino acid sequences in the transmembrane r qions. 
The high affinity of the bovine brain clone for M-sub- 
stituted adenosine analogs and for S-substituted xan- 
thine antagonists, as well as its distinct rank order 
potency, will make it a useful reagent in the study of 
structure-activity relationships and ligand binding 
domains of the A, receptor. 
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